Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796138 | 0.86 | ALDH1A1 (0.39) | ALDH1A1TDP1NOS3NOS1NOS2 | |
| SCHEMBL28326283 | 0.73 | — | — | |
| SCHEMBL5799232 | 0.73 | NOS3 (0.44) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL13685972 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7920979 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11530187 | 0.67 | — | — | |
| SCHEMBL28424185 | 0.66 | SLC6A2 (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL1359000 | 0.66 | — | — | |
| SCHEMBL11135965 | 0.64 | — | — | |
| SCHEMBL8201975 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102731456-B | Antitumor compound, its preparation method and application | UNIV HUAZHONG SCIENCE TECH | 2014-07-09 | — | — | CN | claimed |
| CN-102731456-A | Antitumor compound, its preparation method and application | UNIV HUAZHONG SCIENCE TECH | 2012-10-17 | — | — | CN | claimed |
| JP-58109475-A | — | — | None | — | — | JP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-12383635-B2 | Radiolabelled MGL PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-12 | — | — | US | disclosed |
| EP-4038070-B1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-114555596-B | Radiolabelled MGL PET ligands | 詹森药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119029301-A | Electrolyte for lithium ion battery and lithium ion battery | 中国科学技术大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-1189823-A | Cyclic amidino formulations useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 1998-08-05 | — | — | CN | disclosed |
| EP-0824523-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. Searle & Co. (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996035677-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. SEARLE & CO. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0095495-A1 | SYNTHESIS OF MILBEMYCIN AND AVERMECTIN MACROLIDES | UNIVERSITY PATENTS, INC. (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4408059-A | Spiroketals useful as intermediates in the synthesis of milbemycin and avermectin macrolides | UNIVERSITY PATENTS, INC. (US) | 1983-10-04 | — | — | US | disclosed |
| JP-S58109475-A | 5,5-DISUBSTITUTED ISOXAZOLINE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1983-06-29 | — | — | JP | disclosed |
| WO-1983001953-A1 | SYNTHESIS OF MILBEMYCIN AND AVERMECTIN MACROLIDES | UNIVERSITY PATENTS INC (US) | 1983-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | ALDH1A1 1971/4885TDP1 483/4885NOS3 3516/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | ALDH1A1 587/4885TDP1 1095/4885NOS3 2454/4885 |
| US-12383635-B2 | Radiolabelled MGL PET ligands | MGLL, LPL, LIPC | ALDH1A1 2498/4885TDP1 3233/4885NOS3 3216/4885 |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | MGLL, LPL, LIPC | ALDH1A1 2486/4885TDP1 3052/4885NOS3 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.